Insulet/$PODD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
- Ticker
- $PODD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5,400
- Headquarters
- Acton, United States
- Website
- www.insulet.com
Insulet Metrics
BasicAdvanced
$11B
29.24
$5.30
1.10
-
Price and volume
Market cap
$11B
Beta
1.1
52-week high
$354.88
52-week low
$126.40
Average daily volume
1.5M
Financial strength
Current ratio
2.485
Quick ratio
1.51
Long term debt to equity
0.701
Total debt to equity
0.714
Interest coverage (TTM)
8.77%
Profitability
EBITDA (TTM)
614.9
Gross margin (TTM)
71.07%
Net profit margin (TTM)
12.29%
Operating margin (TTM)
16.89%
Effective tax rate (TTM)
24.14%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
9.71%
Return on equity (TTM)
26.02%
Valuation
Price to earnings (TTM)
29.236
Price to revenue (TTM)
3.55
Price to book
7.55
Price to tangible book (TTM)
8.55
Price to free cash flow (TTM)
40.816
Free cash flow yield (TTM)
2.45%
Free cash flow per share (TTM)
3.794
Growth
Revenue change (TTM)
29.41%
Earnings per share change (TTM)
59.41%
3-year revenue growth (CAGR)
27.73%
10-year revenue growth (CAGR)
25.16%
3-year earnings per share growth (CAGR)
80.81%
10-year earnings per share growth (CAGR)
16.98%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Analyst projections of the future price of Insulet stock.
Bulls say / Bears say
Insulet’s growth remains strong: second-quarter 2026 revenue rose 22.7% at constant currency and adjusted earnings per share increased 41.5%, with revenue above the company’s guidance range. This shows the Omnipod business is still converting demand into earnings. (Insulet Corporation)
International sales offer a meaningful growth engine: Omnipod revenue outside the US grew 32.9% at constant currency in the second quarter, and Insulet raised its full-year international growth outlook to 30%–32%. Its Omnipod 5 launch in Spain adds another market for expansion. (Insulet Corporation, Insulet Corporation)
Product improvements could help keep Omnipod attractive and support future adoption. Insulet launched an upgraded Omnipod 5 algorithm with a lower glucose target and broader compatibility with Abbott’s Libre 3 Plus sensor, while its next-generation Omnipod 6 programme has reported supportive study results. (Insulet Corporation, Drug Delivery Business News)
Weaker early retention and utilisation among type 2 users forced Insulet to cut its 2026 US Omnipod growth outlook to 17%–19% from 20%–22%. If its customer-support changes do not improve retention, this could weigh on recurring pod revenue and growth. (Reuters)
A manufacturing defect led Insulet to correct affected Omnipod lots after reports of serious injuries, and the FDA classified the action as a Class I recall. The issue creates patient-safety and reputational risks, as well as replacement and support costs that Insulet said could reach $50 million. (Reuters, US Food and Drug Administration)
Competition may make it harder to sustain US growth and market share. Jefferies recently cut its price target, citing multiple rival product launches expected over the next year and the risk of share loss. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Upcoming events
No upcoming events
Insulet News
AllArticlesVideos
Insulet Announces Omnipod Discover Now Available in U.S.
Business Wire3 weeks ago
Insulet Targets Type 2 Retention as Omnipod 6 and Global Growth Gain Momentum
MarketBeat1 month ago
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Business Wire2 months ago
Funds containing Insulet
AllUSDEURGBP
Fund name | Fund size | $PODD weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.05% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.05% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.05% |
Xtrackers S&P 500 Equal Weight£XDWE | $16B | 0.22% |
Xtrackers S&P 500 Equal Weight$XDEW | $16B | 0.22% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.